To access a recording of this webcast, please click here.
You will be prompted to register and then the recording will begin.
To access the presentation materials, please click here.
The materials have been updated to reflect the U.S. antitrust agencies’ announcement on Friday that they will be granting early termination of the HSR waiting period, effective March 30, 2020.
As the global business community works hard to respond to rapidly changing market conditions brought on by the COVID-19 pandemic, industry challenges and opportunities may present unexpected antitrust risk, particularly in the high-tech and life sciences industries. Whether it's coordinating with competitors to overcome supply chain challenges for direct-to-consumer subscription services, to creating pharmaceutical joint ventures to work towards a cure for the novel coronavirus, to pricing strategies on third-party e-commerce platform markets – even seemingly innocent conduct could inadvertently violate the antitrust laws. The FTC, DOJ, State AGs and global enforcers around the world have made clear that they will not hesitate to take enforcement action against companies that violate antitrust laws during the worldwide response to the coronavirus.
Cooley’s antitrust team will discuss practical guidance to help companies maximize their opportunities and overcome challenges, while minimizing potential antitrust missteps, including in the areas of managing merger review timelines, creating competitor collaborations, information exchanges and maintaining compliant pricing strategies to avoid allegations of price fixing, bid rigging and price gouging in the US and around the world.
For additional information please email Rebecca Lanz or call +1 202 728 7084.